West Pharmaceutical Services, Inc. — 2018 Form 10-K Summary
Business context and reporting period
West is a global manufacturer of containment, packaging and drug-delivery systems for injectable medicines, serving biologic, generic, pharmaceutical, diagnostic and medical-device customers. Operations are organized into Proprietary Products and Contract-Manufactured Products. The filing covers the fiscal year ended December 31, 2018, with comparative results for 2017 and 2016. International sales represented 55.4% of 2018 consolidated sales.
Key financial metrics
<>| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Net sales | $1,717.4 million | $1,599.1 million | Up 7.4%; up 5.6% excluding currency |
| Gross profit / margin | $545.4 million / 31.8% | $512.9 million / 32.1% | Profit up 6.3%; margin down 0.3 points |
| Operating profit / margin | $240.3 million / 14.0% | $225.8 million / 14.1% | Profit up 6.4%; margin down 0.1 points |
| Net income | $206.9 million | $150.7 million | Up 37.3% |
| Diluted EPS | $2.74 | $1.99 | Up 37.7% |
| Operating cash flow | $288.6 million | $263.3 million | Up $25.3 million |
| Capital expenditures | $104.7 million | $130.8 million | Down $26.1 million |
| Cash and equivalents | $337.4 million | $235.9 million | Up $101.5 million |
| Total debt | $196.1 million | $197.0 million | Down $0.9 million |
| Working capital | $610.7 million | $464.0 million | Up 31.6% |
Proprietary Products sales increased 5.8% to $1,308.6 million, while Contract-Manufactured Products sales increased 12.9% to $409.1 million. Proprietary Products operating profit rose 9.3% to $266.4 million; Contract-Manufactured Products operating profit declined 8.3% to $44.3 million.
Fourth-quarter 2018 sales were $422.5 million, gross profit was $133.2 million, net income was $52.0 million and diluted EPS was $0.69. The filing does not provide a clear comparable fourth-quarter 2017 net income or EPS value in the quarterly table.
Material changes versus the prior comparable period
- Sales growth was supported by high-value components, ready-to-use seals, stoppers and plungers, NovaPure products, pricing actions and higher Contract-Manufactured Products volume. Favorable currency translation contributed $28.6 million to reported sales growth.
- Consolidated gross margin decreased because of lower Contract-Manufactured Products profitability, including plant-consolidation overhead, new-program start-up costs, unfavorable mix, lower development and tooling profitability, and higher raw-material costs.
- Restructuring and related charges totaled $9.1 million in 2018, including $3.1 million of severance, $2.2 million of non-cash asset write-downs and other charges. Management expects annualized savings of $13.5 million to $14.5 million once the plan is complete.
- Net income benefited from a lower effective tax rate of 17.2%, compared with 36.4% in 2017. The 2017 result included a $48.8 million discrete tax charge related to the 2017 Tax Act, while 2018 included a $2.5 million tax benefit from tax-law changes and a $14.3 million benefit associated with share-based payment tax accounting.
- Operating cash flow increased, while investing cash use declined as major capital projects, including the Waterford, Ireland facility, neared completion. The Waterford facility began commercial production in the second half of 2018.
- The company adopted ASC 606 on January 1, 2018, recording an $11.4 million cumulative-effect increase to retained earnings. Reported 2018 net sales were $3.5 million lower and net income $3.0 million lower than they would have been without the adoption.
- The company repurchased 800,000 shares for $70.8 million during 2018 and paid $42.1 million in cash dividends. The quarterly dividend increased to $0.15 per share in the fourth quarter.
Guidance, outlook, risks and unusual items
The filing does not provide a specific 2019 earnings or revenue guidance range. Management expects cash on hand, operating cash flow and available credit to fund foreseeable liquidity needs, and expects to remain in compliance with debt covenants throughout 2019. The company had $268.9 million of available capacity under its $300.0 million multi-currency revolving credit facility at year-end.
- Vial2Bag recall: On January 24, 2019, West voluntarily recalled the Vial2Bag product line because of potential unpredictable or variable dosing under certain conditions. The 2018 results included an $11.3 million provision for product returns. Related inventory was $6.5 million at year-end, and management believed the returned inventory would be saleable in 2019.
- Restructuring: The 2018 plan is expected to be implemented over 12 to 24 months, with anticipated charges of $8.0 million to $13.0 million and capital expenditures of $9.0 million to $14.0 million.
- International and currency exposure: Foreign exchange movements, political and economic conditions, tariffs, regulatory changes and the concentration of international manufacturing and sales could materially affect results.
- Supply chain and commodities: West relies on single-source suppliers for many critical elastomers, aluminum and plastic inputs. Raw-material and energy cost volatility, including petroleum-related elastomer surcharges, may pressure margins.
- Regulatory and product risks: Products and customer products incorporating West technologies require regulatory approvals. Defects, recalls, delayed approvals, intellectual-property disputes or shifts away from injectable drug delivery could adversely affect performance.
- Pensions and obligations: Pension plans were underfunded by $52.5 million and other postretirement plans by $6.0 million at year-end. Total contractual obligations were $396.2 million, including debt, interest, leases and purchase commitments.
- Subsequent events: West entered an agreement to acquire its South Korean distributor, expected to close in April 2019, and authorized an additional 800,000-share repurchase program for 2019.
Most important facts for investors to verify
- Whether the Vial2Bag recall results in additional returns, remediation costs, regulatory action or lost customer demand beyond the $11.3 million provision.
- The sustainability of revenue growth and whether Contract-Manufactured Products margins recover from the 2018 decline.
- The timing and realized savings from the restructuring plan, together with remaining restructuring charges and capital spending.
- The recurring earnings impact after excluding tax benefits, restructuring, currency effects and other unusual items.
- Foreign-exchange, raw-material and single-source supplier exposure, particularly given the 55.4% international sales mix.
- The effect of ASC 606 on revenue timing, contract assets and liabilities, accounts receivable and future comparability.
- Future cash deployment among dividends, share repurchases, acquisitions, capital expenditures and debt reduction.